Could earlier ketamine stop seizures faster?
NCT ID NCT07177235
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether giving the drug ketamine earlier, along with midazolam, can stop prolonged seizures faster in adults. Researchers will compare early versus late ketamine timing in 50 patients with refractory status epilepticus. The goal is to see if earlier use shortens seizure duration.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ketamine and midazolam
- What this could lead to
- If successful, this could show that earlier use of ketamine helps stop prolonged seizures faster, potentially improving outcomes for patients.
- What could go wrong
- This is a small pilot study with only 50 participants, so results may not apply broadly. The timing difference is modest, and the study hasn't started yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults 18 years of age or older 2. Patients with refractory status epilepticus unresponsive to appropriately dosed first line agents administered intravenous or intraosseous and one second line agent 1. First line agents: lorazepam, midazolam, or diazepam 2. Second line agents: phenytoin (20 mg/kg), valproate (40 mg/kg), levetiracetam (60 mg/kg), lacosamide (400 mg) 3. All etiologies of status epilepticus will be included Exclusion Criteria: 1. Exclusively psychogenic non epileptic seizures 2. Pregnant individuals 3. Incarcerated individuals 4. Patients with hypersensitivity to ketamine or any component of the formulation 5. Conditions in which an increase in blood pressure would be hazardous 6. Focal motor status epilepticus 7. Status epilepticus lasting \> 24 hours prior to enrollment (SRSE) 8. Patients with EEG in the ictal-interictal continuum (IIC)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Refractory status epilepticus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.